Press release
Malignant Ascites Clinical Trial Pipeline Gains Momentum: 5+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
Malignant Ascites Pipeline Insights
Explore our latest breakthroughs in Malignant Ascites Research. Learn more about our innovative pipeline today! @ Malignant Ascites Pipeline Outlook- https://www.delveinsight.com/sample-request/malignant-ascites-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Malignant Ascites Pipeline Report
• On February 09, 2026- Dong sheng Zhang conducted a Phase II Expansion Stage To evaluate the efficacy and safety of liposomal irinotecan as monotherapy or in combination with recombinant modified human tumor necrosis factor or bevacizumab, in the treatment of malignant peritoneal effusion in patients who have failed prior standard therapy.
• DelveInsight's Malignant Ascites pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Malignant Ascites treatment.
• The leading Malignant Ascites Companies such as Clover Biopharmaceuticals, YZY Biopharma, Sorrento Therapeutics, Inc., Simcere, PharmaCyte Biotech, Linton Pharm, and others.
• Promising Malignant Ascites Therapies such as M701, Paracentesis, Alfapump, and others.
Stay informed about the cutting-edge advancements in Malignant Ascites treatments. Download for updates and be a part of the revolution in care @ Malignant Ascites Clinical Trials Assessment- https://www.delveinsight.com/sample-request/malignant-ascites-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Malignant Ascites Overview
Ascites is the buildup of fluid in the space around the organs in the abdomen. When ascites is caused by cancer, it is called malignant ascites. The most common malignancies associated with the development of ascites include cancers of the colon breast, lung, pancreas, liver, and lymphoma. Approximately 50% of patients with malignant ascites have peritoneal carcinomatosis with an additional 13% of patients having extensive liver metastases resulting in portal hypertension. Malignant ascites can develop through several mechanisms: blocked lymphatic channels as a result of malignancy, direct production of fluid into the peritoneal cavity by highly active cancers, and when "functional" cirrhosis develops in patients with extensive hepatic metastases resulting in portal hypertension. The development of malignant ascites carries a poor prognosis, with the median survival reported anywhere between 1 and 4 months.
Malignant Ascites Emerging Drugs
• SCB-313: Clover Biopharmaceuticals
With the Trimer-TagTM technology platform, the company have developed SCB-313 as a covalently-linked, native-like trimeric fusion protein which is structurally and functionally differentiated from the dimeric antibody-based structures and other native ligand-based candidates targeting this pathway. They are developing SCB-313 for the treatment of malignant ascites (MA), malignant pleural effusions (MPE), and peritoneal carcinomatosis (PC) to address global unmet medical need of intracavitary malignancies. The drug is currently in Phase I stage of clinical trial evaluation to treat malignant ascites.
Learn more about Malignant Ascites Drugs opportunities in our groundbreaking Malignant Ascites Research and development projects @ Malignant Ascites Unmet Needs- https://www.delveinsight.com/sample-request/malignant-ascites-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Malignant Ascites Companies
Clover Biopharmaceuticals, YZY Biopharma, Sorrento Therapeutics, Inc., Simcere, PharmaCyte Biotech, Linton Pharm, and others.
Malignant ascites pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Malignant Ascites Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Discover the latest advancements in Malignant Ascites treatment by visiting our website. Stay informed about how we're transforming the future of disease @ Malignant Ascites Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/malignant-ascites-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Malignant Ascites Pipeline Report
• Coverage- Global
• Malignant Ascites Companies- Clover Biopharmaceuticals, YZY Biopharma, Sorrento Therapeutics, Inc., Simcere, PharmaCyte Biotech, Linton Pharm, and others.
• Malignant Ascites Therapies- M701, Paracentesis, Alfapump, and others.
• Malignant Ascites Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Malignant Ascites Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Malignant Ascites Pipeline on our website @ Malignant Ascites Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/malignant-ascites-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Malignant ascites: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Malignant ascites - DelveInsight's Analytical Perspective
7. Mid Stage Products (Phase II)
8. Drug name: Company name
9. Drug profiles in the detailed report.....
10. Early Stage Products (Phase I)
11. SCB-313: Clover Biopharmaceuticals
12. Drug profiles in the detailed report.....
13. Inactive Products
14. Malignant ascites Key Companies
15. Malignant ascites Key Products
16. Malignant ascites- Unmet Needs
17. Malignant ascites- Market Drivers and Barriers
18. Malignant ascites- Future Perspectives and Conclusion
19. Malignant ascites Analyst Views
20. Malignant ascites Key Companies
21. Appendix
About Us
DelveInsight is a leading focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and pharma sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Malignant Ascites Clinical Trial Pipeline Gains Momentum: 5+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight here
News-ID: 4399295 • Views: …
More Releases from DelveInsight Business Research LLP
Kinase Inhibitor in Autoimmune Diseases Market Size in the 7MM is projected to g …
DelveInsight's "Kinase Inhibitor in Autoimmune Diseases Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Kinase Inhibitor in Autoimmune Diseases, historical and forecasted epidemiology as well as the Kinase Inhibitor in Autoimmune Diseases market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Kinase Inhibitor in Autoimmune Diseases Market Research Report
• In January 2026- Sanofi conducted a…
FcRn Inhibitors Market Size in the 7MM is projected to grow at a significant CAG …
DelveInsight's report titled "FcRn Inhibitor Market Insight, Competitive Landscape, and Market Forecast- 2034" provides a comprehensive insight into FcRn Inhibitor, including details on the potential patient pool, competitive scenario, and anticipated market trends in the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. The FcRn Inhibitor Market Size is anticipated to increase in the study period due to a direct consequence of an increase in R&D…
Leptomeningeal Metastases Therapeutics Market Size in the 7MM is projected to gr …
DelveInsight's " Leptomeningeal Metastases Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Leptomeningeal Metastases, historical and forecasted epidemiology, as well as the Leptomeningeal Metastases Market Trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Discover Key Insights into the Leptomeningeal Metastases Market with DelveInsight's In-Depth Report @ Leptomeningeal Metastases Treatment Market Size- https://www.delveinsight.com/sample-request/leptomeningeal-metastases-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Leptomeningeal Metastases…
Lupus Nephritis Clinical Trial Pipeline Appears Robust With 35+ Key Pharma Compa …
DelveInsight's "Lupus Nephritis Pipeline Insight 2026" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Lupus Nephritis pipeline landscape. It covers the Lupus Nephritis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Lupus Nephritis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates…
More Releases for Malignant
Malignant Mesothelioma Market Size and Forecast
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Malignant Mesothelioma Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
The impact of manufacturers on the market is significant across various industries, influencing supply chains, consumer choices, and economic growth. Manufacturers are key players in…
Adult Malignant Glioma Therapeutics Market - Defying the Tumor, Empowering Survi …
Newark, New Castle, USA - new report, titled Adult Malignant Glioma Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Adult Malignant Glioma Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Adult Malignant Glioma Therapeutics market. The report offers…
Malignant Mesothelioma-Pipeline Review H2 2018
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Human Parainfluenza Virus 3 Infections-Pipeline Review, H2 2018, provides an overview of the Human Parainfluenza Virus 3 Infections (Infectious Disease) pipeline landscape.
Human parainfluenza virus 3 is a life-threatening infection that causes respiratory illnesses in infants and young children. Symptoms include fever, cough, runny nose, croup, bronchiolitis, wheezing and sore throat. Treatment includes over-the-counter medications for pain and fever.
Report Highlights
Publisher's Pharmaceutical…
Malignant Mesothelioma-Pipeline Review H2 2018
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Mesothelioma-Pipeline Review, H2 2018, provides an overview of the Malignant Mesothelioma (Oncology) pipeline landscape.
Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result,…
Malignant Melanoma Drug Market Malignant Melanoma Clinical Pipeline Report
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to Malignant Melanoma
2. Malignant Melanoma Drug Mechanism of Action
3. Global Malignant Melanoma Market Analysis
3.1 Current Market Scenario
3.2 Global Malignant Melanoma Pipeline Overview
4. Global Malignant Melanoma Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges
5. Global Malignant Melanoma Drug Market Future Prospects
6. Global Malignant Melanoma Clinical Pipeline By…
Rising Number of People Diagnosed with Malignant Glioma Supports the Growth of t …
Glioma is a type of tumor that occurs in brain or spine. It is a group of brain tumor that includes oligodendrogliomas and astrocytomas. Gliomas include all types of brain tumors arising from supportive tissue of the brain. Malignant glioma is the most common type of brain tumor observed in adults globally. Collectively they contribute around 40% of the total cases diagnosed with brain tumor. In the last decade, there…
